-
Featured NewsNovartis Hematology: Working to help ensure patients are getting the access they need
-
Media ReleaseNew research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity
-
Media ReleaseNovartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
-
Media ReleaseNovartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
-
Media ReleaseNovartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
-
Media ReleaseNovartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
-
Media ReleaseNovartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
-
Media ReleaseNovartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
-
Media ReleaseNovartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
-
Story
Partnering for improved cancer care around the globe -
Story
New drugs could offer hope for malaria patients -
Story
Making healthcare sustainable in the developing world